AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 12838282 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporin A (CSA)
Number of subjects: 62
Study 11339012 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium levels in patients with MVPS
Number of subjects: 50
Study 11339012 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) magnesium levels
Number of subjects: 50
Study 11339012 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of magnesium levels
Number of subjects: 50
Study 11339012 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of magnesium deficiency
Number of subjects: 50
Study 11339012 — intervention group
Group type: EXPERIMENTAL
Intervention: Histograms of magnesium concentration values
Number of subjects: 50
Study 8976466 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving treatment (PST)
Number of subjects: 0
Study 1732343 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin 0.025% cream
Number of subjects: 14
Study 1732343 — intervention group
Group type: COMPARATOR
Intervention: Vehicle treatment
Number of subjects: 14
Study 6397332 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiramycin 500 mg 3-times daily for 3 days
Number of subjects: 100
Study 6397332 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin 500 mg 3-times daily for 5 days
Number of subjects: 100
Study 30089580 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadolinium magnetic resonance imaging (Gd‐MRI)
Number of subjects: 2
Study 30089580 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated 18 F‐fludeoxyglucose positron emission tomography (18F‐FDG‐PET) imaging
Number of subjects: 2
Study 30721586 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 15 mg + Furosemide 20 mg (TH group)
Number of subjects: 64
Study 30721586 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan 7.5 mg + Furosemide 20 mg (TI group)
Number of subjects: 64
Study 30721586 — intervention group
Group type: COMPARATOR
Intervention: Furosemide 40 mg + Spironolactone 50 mg (C group)
Number of subjects: 64
Study 24709498 — intervention group
Group type: EXPERIMENTAL
Intervention: Crystalloid + albumin group (n=33)
Number of subjects: 63
Study 24709498 — intervention group
Group type: COMPARATOR
Intervention: Crystalloid group (n=30)
Number of subjects: 63
Study 23163605 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-restrictive slogans (e.g., 'Don't drink')
Number of subjects: 91
Study 20230352 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty
Number of subjects: 0
Study 20230352 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 18166312 — intervention group
Group type: EXPERIMENTAL
Intervention: Adequate prenatal care (Kotelchuck index)
Number of subjects: 420
Study 18166312 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate prenatal care (Kotelchuck index)
Number of subjects: 420
Study 18166312 — intervention group
Group type: EXPERIMENTAL
Intervention: Unscheduled obstetric visits
Number of subjects: 420
Study 18166312 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple unscheduled visits
Number of subjects: 420
Study 18166312 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional unscheduled encounters
Number of subjects: 420
Study 18166312 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of unscheduled visits
Number of subjects: 420
Study 15671112 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG (10,000 IU, single IM injection on day 19)
Number of subjects: 12
Study 15671112 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (200 mg intravaginally, days 18-27)
Number of subjects: 12
Study 15671112 — intervention group
Group type: COMPARATOR
Intervention: Control (natural cycle)
Number of subjects: 12
Study 15671112 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG
Number of subjects: 12
Study 15671112 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 12
Study 12025445 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron therapy for children with IDA after a 3-month follow-up period.
Number of subjects: 35
Study 12025445 — intervention group
Group type: COMPARATOR
Intervention: Control group (children without IDA).
Number of subjects: 35
Study 10346547 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention practices (using patient self-assessment data)
Number of subjects: 1651
Study 10346547 — intervention group
Group type: COMPARATOR
Intervention: Usual care practices (control group)
Number of subjects: 1651
Study 8600086 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 51
Study 8600086 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential PCI
Number of subjects: 51
Study 8600086 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent or sandwiched PCI
Number of subjects: 51
Study 8600086 — intervention group
Group type: COMPARATOR
Intervention: Matched controls
Number of subjects: 51
Study 11188598 — intervention group
Group type: COMPARATOR
Intervention: Healthy children
Number of subjects: 32
Study 11188598 — intervention group
Group type: EXPERIMENTAL
Intervention: JRA patients
Number of subjects: 32
Study 6179344 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral retinoids in combination with bleomycin, cyclophosphamide, prednisone, and transfer factor
Number of subjects: 10
Study 6179344 — intervention group
Group type: COMPARATOR
Intervention: Control group (no retinoids, only chemotherapy with bleomycin, cyclophosphamide, and prednisone)
Number of subjects: 10
Study 31260437 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-segment fixation (Group A)
Number of subjects: 18
Study 31260437 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-segment fixation (Group B)
Number of subjects: 18
Study 31260437 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-segment fixation (Group C)
Number of subjects: 18
Study 31260437 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper adjacent segments
Number of subjects: 18
Study 28212652 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person behavioural support
Number of subjects: 68
Study 28212652 — intervention group
Group type: COMPARATOR
Intervention: Self-help booklet
Number of subjects: 68
Study 28212652 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week reduction programme
Number of subjects: 68
Study 28212652 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week reduction programme
Number of subjects: 68
Study 25639187 — intervention group
Group type: EXPERIMENTAL
Intervention: Early, ED-based referrals to palliative care
Number of subjects: 134
Study 25639187 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (physician-driven consultation)
Number of subjects: 134
Study 24320695 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional magnetic stimulation (FMS) of 30 Hz applied for suprahyoid muscles for 10 min (total 1200 pulses)
Number of subjects: 20
Study 24320695 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation applied for 10 min at the same site
Number of subjects: 20
Study 23017355 — intervention group
Group type: EXPERIMENTAL
Intervention: Raltegravir
Number of subjects: 81
Study 23017355 — intervention group
Group type: COMPARATOR
Intervention: PI/r
Number of subjects: 81
Study 19573999 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated group therapy (12 sessions)
Number of subjects: 61
Study 19573999 — intervention group
Group type: COMPARATOR
Intervention: Group drug counseling (control)
Number of subjects: 61
Study 17371430 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with no experience of clinical trials
Number of subjects: 78
Study 17371430 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who had previously participated in an RCT
Number of subjects: 78
Study 17371430 — intervention group
Group type: COMPARATOR
Intervention: Research nurses
Number of subjects: 78
Study 17371430 — intervention group
Group type: COMPARATOR
Intervention: Comparison between patient groups
Number of subjects: 78
Study 16734121 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic fibroblast growth factor (bFGF) in serum
Number of subjects: 30
Study 16734121 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble E-selectin (sE-sel) in serum
Number of subjects: 30
Study 16734121 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF and sE-sel in synovial fluid (SF)
Number of subjects: 30
Study 16734121 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF and sE-sel correlation with functional class stages
Number of subjects: 30
Study 16734121 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF in SF and joint derangement
Number of subjects: 30
Study 16734121 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF and sE-sel correlation
Number of subjects: 30
Study 16734121 — intervention group
Group type: EXPERIMENTAL
Intervention: bFGF and sE-sel with clinical parameters
Number of subjects: 30
Study 11705417 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS)
Number of subjects: 0
Study 11705417 — intervention group
Group type: COMPARATOR
Intervention: Angiography
Number of subjects: 0
Study 11059999 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (induced by a 100 g amino acid drink following an overnight fast)
Number of subjects: 19
Study 11059999 — intervention group
Group type: COMPARATOR
Intervention: Control drink (placebo)
Number of subjects: 19
Study 9103106 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical time intervention plus usual services
Number of subjects: 96
Study 9103106 — intervention group
Group type: COMPARATOR
Intervention: Usual services only
Number of subjects: 96
Study 9114915 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (80 mg) administered at mid-meal (group A)
Number of subjects: 24
Study 9114915 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (80 mg) administered 1 hour after mid-meal (group B)
Number of subjects: 24
Study 9114915 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat (80 mg) administered 2 hours after mid-meal (group C)
Number of subjects: 24
Study 9114915 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group D) administered 2 hours after mid-meal
Number of subjects: 24
Study 3540876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 10 mg
Number of subjects: 120
Study 3540876 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 120
Study 3540876 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 5 mg
Number of subjects: 120
Study 3540876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31594895 — intervention group
Group type: EXPERIMENTAL
Intervention: In-depth interviews with patients regarding their experiences accessing care for hypertension.
Number of subjects: 20
Study 31594895 — intervention group
Group type: EXPERIMENTAL
Intervention: Public education on hypertension and better communication between healthcare professionals and patients.
Number of subjects: 20
Study 31594895 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminders from family members for adherence to antihypertensive medications.
Number of subjects: 20
Study 31594895 — intervention group
Group type: EXPERIMENTAL
Intervention: Training healthcare professionals for effective communication.
Number of subjects: 20
Study 31594895 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of the names or purpose of their medications.
Number of subjects: 20
Study 29467829 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical offloading procedure (percutaneous flexor tenotomy, mini‐invasive floating metatarsal osteotomy or Keller arthroplasty)
Number of subjects: 100
Study 29467829 — intervention group
Group type: COMPARATOR
Intervention: Best available non-surgical treatment (offloading cast applied for up to 12 weeks)
Number of subjects: 100
Study 27480291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligation of major branches during ITA anastomosis to the left anterior descending (LAD) coronary artery (Group I, 25 patients)
Number of subjects: 53
Study 27480291 — intervention group
Group type: COMPARATOR
Intervention: No ligation of major branches during ITA anastomosis (Group II, 28 patients)
Number of subjects: 53
Study 24041199 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Internet-based guided self-help treatment (8 weeks)
Number of subjects: 132
Study 24041199 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized disorder-specific Internet-based treatment (8 weeks)
Number of subjects: 132
Study 24041199 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 132
Study 22751757 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended ALS training (1-day course supplemented with e-learning)
Number of subjects: 3732
Study 22751757 — intervention group
Group type: COMPARATOR
Intervention: Conventional ALS training (2-day course)
Number of subjects: 3732
Study 20362834 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: Anterior capsular release including the anterior band of the IGHL
Number of subjects: 74
Study 20362834 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 2: Extended release inferiorly and posteriorly
Number of subjects: 74
Study 20362834 — intervention group
Group type: COMPARATOR
Intervention: Control: No additional release of the inferior glenohumeral ligament
Number of subjects: 74
Study 18407004 — intervention group
Group type: EXPERIMENTAL
Intervention: Unconditional incentives
Number of subjects: 12289
Study 18407004 — intervention group
Group type: EXPERIMENTAL
Intervention: $2 bill prepaid incentive and promise of $20 for retention
Number of subjects: 12289
Study 18407004 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-value incentives
Number of subjects: 12289
Study 18407004 — intervention group
Group type: EXPERIMENTAL
Intervention: Small prepaid monetary incentive ($2 or $5)
Number of subjects: 12289
Study 15611004 — intervention group
Group type: COMPARATOR
Intervention: Standard tibial fixation with 7 x 25‐mm metal interference screw
Number of subjects: 56
Study 15611004 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal interference screw with supplementary staple fixation
Number of subjects: 56
Study 12058094 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release divalproex sodium
Number of subjects: 0
Study 12058094 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10474762 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexrazoxane
Number of subjects: 1070
Study 8528115 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT (Electrical Impedance Tomography) imaging during voluntary breathing maneuvers in humans and artificial ventilation in pigs.
Number of subjects: 17
Study 8528115 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT during artificial ventilation at different ventilation rates and during stepwise passive emptying and filling of lungs.
Number of subjects: 17
Study 8528115 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT functional imaging with 16 electrodes placed around the thorax.
Number of subjects: 17
Study 8528115 — intervention group
Group type: EXPERIMENTAL
Intervention: EIT with additional evaluation procedure of functional imaging.
Number of subjects: 17
Study 1961623 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure oxygen (3 L/min) by a nasal probe
Number of subjects: 31
Study 1961623 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pure oxygen)
Number of subjects: 31
Study 31471739 — intervention group
Group type: EXPERIMENTAL
Intervention: WLI-NBI cystoscopy
Number of subjects: 600
Study 31471739 — intervention group
Group type: COMPARATOR
Intervention: WLI-WLI cystoscopy
Number of subjects: 600
Study 30376108 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir 500 mg twice daily
Number of subjects: 198
Study 30376108 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study 30376108 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir
Number of subjects: 198
Study 30376108 — intervention group
Group type: EXPERIMENTAL
Intervention: Valaciclovir and Placebo
Number of subjects: 198
Study 28923375 — intervention group
Group type: EXPERIMENTAL
Intervention: Feldenkrais Method (FM) - Awareness Through Movement classes (30 classes)
Number of subjects: 32
Study 28923375 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) - no movement-based intervention
Number of subjects: 32
Study 25516497 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal Vitamin C and E supplementation
Number of subjects: 0
Study 25516497 — intervention group
Group type: COMPARATOR
Intervention: Control (no Vitamin C and E supplementation)
Number of subjects: 0
Study 23802602 — intervention group
Group type: EXPERIMENTAL
Intervention: DIALOG+ intervention, where key workers are trained to use DIALOG+ with each patient over a six-month period.
Number of subjects: 180
Study 23802602 — intervention group
Group type: COMPARATOR
Intervention: Control group where patients rate their satisfaction with life and treatment on a tablet.
Number of subjects: 180
Study 21075600 — intervention group
Group type: EXPERIMENTAL
Intervention: MATRICS Consensus Cognitive Battery (MCCB)
Number of subjects: 323
Study 21075600 — intervention group
Group type: EXPERIMENTAL
Intervention: UCSD Performance-based Skills Assessment-Brief (UPSA-B)
Number of subjects: 323
Study 19107321 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed infrared light therapy (PILT) administered to one foot, 24 treatments (3 times/week for 8 weeks, 30 min each)
Number of subjects: 22
Study 19107321 — intervention group
Group type: COMPARATOR
Intervention: Control foot (no treatment)
Number of subjects: 22
Study 17531577 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg
Number of subjects: 740
Study 17531577 — intervention group
Group type: EXPERIMENTAL
Intervention: rosuvastatin 20 mg
Number of subjects: 740
Study 17531577 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 10 mg
Number of subjects: 740
Study 17531577 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin 20 mg
Number of subjects: 740
Study 15356085 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (62.5 mg/d) plus metformin (850 mg/d) and ethinylestradiol-drospirenone (30 microg plus 3 mg, 21 d/month)
Number of subjects: 40
Study 15356085 — intervention group
Group type: COMPARATOR
Intervention: Control group (metformin (850 mg/d) and ethinylestradiol-drospirenone (30 microg plus 3 mg, 21 d/month) without flutamide
Number of subjects: 40
Study 11425999 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone MR imaging in Group 1 (healthy volunteers and patients with herniated disk)
Number of subjects: 56
Study 11425999 — intervention group
Group type: COMPARATOR
Intervention: Supine MR imaging in Group 3 (patients who previously had tethered cord surgery)
Number of subjects: 56
Study 11425999 — intervention group
Group type: COMPARATOR
Intervention: Supine MR imaging in Group 2 (patients clinically suspected of having a tethered cord)
Number of subjects: 56
Study 9722840 — intervention group
Group type: EXPERIMENTAL
Intervention: PTA with selective stent placement
Number of subjects: 0
Study 9722840 — intervention group
Group type: COMPARATOR
Intervention: Primary stent placement
Number of subjects: 0
Study 9722840 — intervention group
Group type: COMPARATOR
Intervention: PTA alone
Number of subjects: 0
Study 8162994 — intervention group
Group type: EXPERIMENTAL
Intervention: Averaging several forced expirations
Number of subjects: 46
Study 8162994 — intervention group
Group type: EXPERIMENTAL
Intervention: Single curves selected in eight different ways
Number of subjects: 46
Study 8162994 — intervention group
Group type: COMPARATOR
Intervention: Prior inhalation of a bronchodilator aerosol
Number of subjects: 46
Study 8162994 — intervention group
Group type: EXPERIMENTAL
Intervention: Truncation by volume at levels between 75‐99% of forced vital capacity (FVC)
Number of subjects: 46
Study 2607590 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroids
Number of subjects: 6
Study 2607590 — intervention group
Group type: COMPARATOR
Intervention: Elemental diet
Number of subjects: 6
Study 824535 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG) 40 mg
Number of subjects: 17
Study 824535 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (DSCG) 40 mg with ethanol (0-75 g/kg)
Number of subjects: 17
Study 31218390 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile-bearing TKA
Number of subjects: 160
Study 31218390 — intervention group
Group type: COMPARATOR
Intervention: Fixed-bearing TKA
Number of subjects: 160
Study 31889152 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (n=37)
Number of subjects: 72
Study 31889152 — intervention group
Group type: COMPARATOR
Intervention: Standard anticoagulation (enoxaparin and warfarin, n=35)
Number of subjects: 72
Study 27938498 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise
Number of subjects: 108
Study 27938498 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 108
Study 25444990 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Z Trendelenburg position
Number of subjects: 50
Study 25444990 — intervention group
Group type: COMPARATOR
Intervention: Trendelenburg position
Number of subjects: 50
Study 23530484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1781
Study 23530484 — intervention group
Group type: COMPARATOR
Intervention: Implantable cardioverter defibrillator (ICD) therapy alone
Number of subjects: 1781
Study 21570509 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 15570
Study 21570509 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban 5 mg twice daily
Number of subjects: 15570
Study 21570509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15570
Study 19571570 — intervention group
Group type: EXPERIMENTAL
Intervention: Food challenge test (double-blind, placebo-controlled)
Number of subjects: 40
Study 19571570 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 40
Study 19571570 — intervention group
Group type: EXPERIMENTAL
Intervention: Food challenge test (in patients with respiratory reactions)
Number of subjects: 40
Study 16753049 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient polypectomy
Number of subjects: 40
Study 16753049 — intervention group
Group type: COMPARATOR
Intervention: Daycase polypectomy
Number of subjects: 40
Study 15630143 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium citrate (0.5 g x kg(−1) body mass in 1.5 litres of solution)
Number of subjects: 10
Study 15630143 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink (equal volume)
Number of subjects: 10